Skip to main content
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: Free Radic Biol Med. 2012 Jun 6;53(5):1123–1138. doi: 10.1016/j.freeradbiomed.2012.05.036

Figure 1. MitoQ and Mito-CP pretreatment dose-dependently attenuates hepatic I/R injury.

Figure 1

Panel A: Chemical structures of MitoQ and Mito-CP.

Panels B and C: Serum transaminases ALT and AST levels in sham-operated mice treated with vehicle or in mice exposed to 1 h of hepatic ischemia followed by 6 h of reperfusion (I/R 6h) pretreated with vehicle, MitoQ or Mito-CP (0.3, 1 and 3 mg/kg i.p., n=6–21/group).

Panel D: Serum ALT and AST levels in sham operated mice treated with vehicle, MitoQ or Mito-CP (n=6–21/group) or in mice exposed to 1 h of hepatic ischemia followed by 2, 6 and 24 hours of reperfusion (I/R 2h, 6 h and 24h) pretreated with vehicle or MitoQ/Mito-CP (3 mg/kg i.p.). The peak damaged occurs at I/R 6h, and MitoQ/Mito-CP is able to attenuate the inflicted injury at any point investigated. *P<0.05 sham control vs. I/R; #P<0.05 I/R vs. corresponding I/R+ MitoQ/Mito-CP.